Alligator Bioscience Announces Poster Presentation on ATOR-4066 at the AACR Annual Meeting 2023
Presentation highlights potential of ATOR-4066 to induce strong anti-tumor responses in patients with CEACAM5-expressing tumors Data strongl ...
Alligator Bioscience Announces Completion of Patient Enrolment in Mitazalimab OPTIMIZE-1 Phase 2 Trial in Pancreatic Cancer and Confirms Timeline for Top-Line Data in Q1 2024
OPTIMIZE-1 is assessing the safety and efficacy of mitazalimab in combination with mFOLFIRINOX in 1st line metastatic pancreatic cancer Inte ...
Alligator Bioscience Announces FDA Authorization to Initiate Mitazalimab OPTIMIZE-2 Phase 2 Trial in Urothelial Carcinoma
OPTIMIZE-2 is a Phase 2 study to assess the safety and efficacy of mitazalimab in combination with a PD-1 inhibitor in patients affected by ...
Notice of extraordinary general meeting in Alligator Bioscience AB
The shareholders of Alligator Bioscience AB, Reg. No. 556597-8201, are invited to the extraordinary general meeting to be held on Monday 24 ...
Alligator Bioscience Announces KOL Interview on Mitazalimab and the Positive Interim Results from the OPTIMIZE-1 Phase 2 Trial in Pancreatic Cancer
Interview features OPTIMIZE-1 Principal Investigator Jean-Luc Van Laethem from Erasmus Hospital and Alligator CMO Sumeet Ambarkhane OPTIMIZE ...
Change in Employee Representatives to the Board of Directors of Alligator Bioscience AB
Alligator Bioscience AB (publ) today announces that Tova Landström, PhD, Medical Science Director at Alligator, has been appointed as employ ...
Change in Employee Representatives to the Board of Directors of Alligator Bioscience AB
Laura von Schantz, employee representative, has resigned from the Alligator Bioscience AB Board of Directors, effective February 14, 2023, f ...
Alligator Bioscience & Aptevo Therapeutics Announce Dosing of First Patient with ALG.APV-527 in Phase 1 Clinical Trial
Trial to Evaluate Safety, Tolerability and Clinical Activity in Solid Tumors Expressing 5T4 Lund, Sweden, and Seattle, Washington, February ...
Alligator Bioscience Announces the Promotion of Laura von Schantz to Chief Technology Officer
Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces the promotion of Laura von Schantz to Chief Technology O ...